There’s a lot of hype and noise of late surrounding the Iovance TIL therapy licensed under a CRADA from the NCI based on Dr Steven Rosenberg’s work.

Another Brick in the Wall for TIL therapies?

A few years ago many acadenics vehemently argued that TILs wouldn’t go much further than metastatic melanomas (cutaneous or uveal) and certainly there were dramatic responses seen from the before, during and after photos, as anyone who attended AACR in 2013 will attest.

Seven years on, the TIL topic is back in fashion again – is the hype justified or are the plaudits based more on a wing and a prayer?

We have some firm views to share on this topic…

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the first annual AACR20 virtual meeting subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by